Brighter and lighter days ahead
Sooma tDCS™ – accessible, safe, and effective brain stimulation treatment for depression and chronic pain. Easy solution for better patient care and shorter queues. First and only EU MDR-approved tDCS system.
Depression treatment
The next evolution in treating depression is here. Sooma tDCS is a revolutionary noninvasive brain stimulation treatment that effectively relieves patient symptoms – as well as patient queues at the clinic.
Pain management
Chronic pain conditions typically involve a complex array of symptoms – to which Sooma tDCS brain stimulation is the simple, innovative, and drug-free solution. Help the brain drive the pain away.
About Sooma Medical
Sooma Medical has been trailblazing better health and care from Finland since 2013. Today, Sooma tDCS is the most prescribed tDCS treatment in the world. Read more about who we are – and why we care.
What is Sooma tDCS™?
Sooma tDCS combines pioneering brain stimulation technology with remote protocol management in one easy-to-use system for scalable treatment of depression and chronic pain.
Delivered through a portable device, the treatment utilizes transcranial direct current stimulation (tDCS) to relieve symptoms, with online treatment monitoring and easy adjustments for data-driven clinical decisions. It’s noninvasive, drug-free, and proven effective.
Improvement of symptoms typically within 3 weeks
without systemic side effects
Safe, high-quality, and scalable care
through a cost-effective solution
Increased patient flows and shorter queues
via optimized resources and remote care
Easy adoption and onboarding
with simple treatment protocols and user training
Results by the numbers
25,000+
patients treated in more than 35 countries
55%
of patients experienced relief in as little as 3 weeks in large peer-reviewed study*
150+
hospitals and clinics providing Sooma tDCS treatment
500,000+
treatment sessions administered worldwide for both research and patient care
* 1 Lõokene M, Markov N, Nikander M, Neuvonen T, Dilkov D. Reduction of symptoms in patients with major depressive disorder after transcranial direct current stimulation treatment: A real-world study. Journal of Affective Disorders Reports, Volume 8, 2022. https://doi.org/10.1016/j.jadr.2022.100347.
Broad availability
Sooma tDCS treatment is available through clinicians in more than 35 countries.
What do clinicians and patients think?
Sooma tDCS has helped thousands of patients find relief and a better quality of life. But don’t just take our word for it – read what clinicians and patients have to say about the benefits of our noninvasive brain stimulation treatment.
Meet us at upcoming events
14 – 17 November 2024, Mexico City, Mexico
Learn more
27 – 30 November 2024, Rennes, France
Learn more
27 – 30 November, Berlin, Germany
Learn more